Chordate is a Swedish public limited company. Chordate complies with the Swedish Companies Act (2005: 551) and will follow the rules and recommendations that follow from the company’s listing on Nasdaq First North Growth Market, as well as the praxis for good practice in the stock market. In addition, the company complies with the provisions stipulated in Chordate’s articles of association.
The Swedish Code of Corporate Governance (the “Code”) does not have to be applied by companies whose shares are traded on Nasdaq First North Growth Market. Chordate is already applying certain aspects of the Code and intends to expand the application in step with the Company’s development and growth.
We are a Swedish medical technology company listed on Nasdaq First North Growth Market.
Chordate has spent more than 10 years developing the treatment Ozilia™, which is based on Kinetic Oscillation Stimulation, a technique for treating chronic migraine and chronic rhinitis. We have a patent on Ozilia™ in the EU and the United States, as well as many other countries.
We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.
Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.